Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°£¼¼Æ÷¾Ï ȯÀÚ¿¡¼­ÀÇ BÇü ¹× CÇü °£¿° ¹ÙÀÌ·¯½º Ç¥½ÄÀÚÀÇ ÃøÁ¤ Prevalence of Hepatitis B and C Viral Markers in Patients with Hepatocellular Carcinoma in Korea

´ëÇѾÏÇÐȸÁö 1991³â 23±Ç 4È£ p.723 ~ 727
¼Ò¼Ó »ó¼¼Á¤º¸
Han, Byung-Hoon/ÇѺ´ÈÆ Lee, Sung-YK/Koo, Ja-Young/Park, Byung-Chae/ÀÌ»ó¿í/±¸ÀÚ¿µ/¹Úº´Ã¤

Abstract

°£¼¼Æ÷¾ÏÈ­ÀÚ 118¸í ¹× ´ëÁ¶±º 231¸íÀ» ´ë»óÀ¸·Î ÇÏ¿© HBsAg,anti-HBc ¹× anti-HCV¸¦ ÃøÁ¤ÇÏ¿´´ø ¹Ù ´ÙÀ½ÀÇ°á°ú¸¦ ¾ò¾ú´Ù.
1)´ëÁ¶±º 231¸í¿¡ ´ëÇÑ HBsAg,anti-HBc ¹× anti-HCV ¾ç¼º·üÀº °¢°¢ 13.0%,84.4%¹× 1.3%¿´´Ù.
2)°£¼¼Æ÷¾ÏȯÀÚ 118¸í¿¡ ´ëÇÑ HBsAg,anti-HBc ¹× anti-HCV ¾ç¼º·üÀº °¢°¢ 54.2%,94.9%alc 12.7%·Î¼­ ´ëÁ¶±º¿¡ ºñÇØ ¸ðµÎ À¯ÀÇÇÑ ¾ç¼º·üÀÇ Â÷À̸¦ º¸¿´´Ù.
3)HBsAg¾ç¼ºÀÎ °£¼¼Æ÷¾ÏȯÀÚ 64¸íÁß 2¸í(1.7%)¿¡¼­ anti-HCV¾ç¼ºÀ̾úÀ¸³ª HBsAgÀ½¼ºÀÎ °£¼¼Æ÷¾ÏȯÀÚ 54¸íÁß¿¡´Â 13¸í(12.1%)¿¡¼­ anti-HCV¾ç¼º·üÀ» º¸¿´´Ù.
4)HBsAg,À½¼º ¹× ani-HCV¾ç¼ºÀ» º¸ÀÎ °£¼¼Æ÷¾ÏȯÀÚ 13¿¹ Áß 11¿¹°¡ anti-HBc ¾ç¼ºÀ» º¸¿´°í 2¿¹¿¡¼­´Â anti-HBc°¡ À½¼ºÀ¸·Î ³ªÅ¸³ª¼­ °£¼¼Æ÷¾ÏÈ­ÀÚ¿¡¼­ anti-HBc°¡ À½¼ºÀ¸·Î ³ªÅ¸³ª¼­ °£¼¼Æ÷¾ÏȯÀÚ¿¡¼­ÀÇ anti-HCV ¾ç¼º·üÀº HBV Ç¥½ÄÀÚµé Áß anti-HBcÀÇ ÃâÇö°ú ±ä¸»Èù ¿¬°ü¼ºÀ» º¸¿´´Ù.
5)HBsAg ¾ç¼º anti-HBc ¾ç¼º ¹× anti-HCV ¾ç¼º¹ÝÀÀÀ» º¸ÀÌ´Â °£¼¼Æ÷¾Ï ȯÀÚµéÀÇ Æò±Õ ¿¬·ÉÀº 43¼¼·Î¼­ HBsAg ¾ç¼º,anti-HBc ¾ç¼º ¹× anti-HCV À½¼º±ºÀÇ Æò±Õ¿¬·É(48.6¼¼)º¸´Ù 5³â Á¤µµ ³·¾ÒÀ¸³ª Åë°èÀû À¯ÀǼºÀº ¾ø¾ú´Ù.
6)HBsAg,À½¼º ¹× anti-HBc¾ç¼º ¹× anti-HCV¾ç¼ºÀÎ °£¼¼Æ÷¾ÏȯÀÚÀÇ Æò±Õ¿¬·ÉÀº 56.7¼¼·Î¼­ HBsAg,À½¼º ani-HBc¾ç¼º ¹× anti-HCVȯÀÚ±ºÀÇ Æò±Õ¿¬·É(53.7¼¼)°ú´Â À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù.
7)HBsAg,À½¼ºÀÎ °æ¿ì¿¡´Â anti-HBc¾ç¼º ¹× anti-HCVÀÇ °£¼¼Æ÷¾Ï ¹ß»ý¿¡ ´ëÇÑ »ó´ëÀû À§Çèµµ´Â 4.7·Î¼­ Åë°èÀû À¯ÀǼºÀ» º¸¿´À¸³ª HBsAg°¡ ¾ç¼ºÀÎ °æ¿ì¿¡¼­´Â ±× »ó´ëÀû À§Çèµµ°¡ 1.5·Î¼­ Åë°èÀû À¯ÀǼºÀÌ ¾ø¾ú´Ù.
ÀÌ»óÀÇ °á°ú·Î¼­ Çѱ¹¿¡¼­´Â ¾ÆÁ÷ °£¼¼Æ÷¾ÏÀÇ°¡Àå Áß¿äÇÑ ¿øÀÎÀº BÇü°£¿° ¹ÙÀÌ·¯½ºÀ̸ç HCV´Â HBsAg°¡ À½¼ºÀÎ °æ¿ì¿¡¤Ã ¸¸¼º °£¿° ¹× °£°æº¯ÁõÀ» À¯¹ß½ÃÅ´À¸·Î¼­ ÀÌÂ÷ÀûÀ¸·Î °£¼¼Æ÷¾ÏÀǹ߻ý¿¡ °ü·ÃµÉ ¼ö ÀÖÀ» °ÍÀ¸·Î ÃßÁ¤µÇ¾ú´Ù.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS